Multicenter Phase II trial evaluates AdAPT-001 for resistant tumors, showing promising efficacy

Anthony Paul Conley, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a multicenter Phase II trial (NCT04673942) evaluating AdAPT-001, an oncolytic adenovirus armed with a "TGF-β trap," with or without a checkpoint inhibitor (CI) in resistant patients, some of whom had previously failed CI therapy. In the study, 36 patients received AdAPT-001, with 25 patients undergoing combination therapy. The study reported manageable adverse events and notable outcomes, including a high objective response rate (ORR) of 29.1% and a clinical benefit rate of 62.5%, suggesting potential efficacy in refractory tumors, especially cutaneous sarcomas. Importantly, when including patients treated beyond disease progression, the response rate increased to the high 30% range. Additionally, the six-month progression-free survival rate was around 30-40%, showing significant improvement compared to historical controls. Notably, 70% of these patients had received prior immune checkpoint therapy, indicating that AdAPT-001 could benefit those resistant to previous immunotherapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.